These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38421180)

  • 21. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
    Cheng YW; Chao TL; Li CL; Wang SH; Kao HC; Tsai YM; Wang HY; Hsieh CL; Lin YY; Chen PJ; Chang SY; Yeh SH
    mBio; 2021 Aug; 12(4):e0058721. PubMed ID: 34311586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.
    Antia A; Alvarado DM; Zeng Q; Casorla-Perez LA; Davis DL; Sonnek NM; Ciorba MA; Ding S
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
    Yamasoba D; Kimura I; Nasser H; Morioka Y; Nao N; Ito J; Uriu K; Tsuda M; Zahradnik J; Shirakawa K; Suzuki R; Kishimoto M; Kosugi Y; Kobiyama K; Hara T; Toyoda M; Tanaka YL; Butlertanaka EP; Shimizu R; Ito H; Wang L; Oda Y; Orba Y; Sasaki M; Nagata K; Yoshimatsu K; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Kuramochi J; Seki M; Fujiki R; Kaneda A; Shimada T; Nakada TA; Sakao S; Suzuki T; Ueno T; Takaori-Kondo A; Ishii KJ; Schreiber G; ; Sawa H; Saito A; Irie T; Tanaka S; Matsuno K; Fukuhara T; Ikeda T; Sato K
    Cell; 2022 Jun; 185(12):2103-2115.e19. PubMed ID: 35568035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants.
    Lusvarghi S; Stauft CB; Vassell R; Williams B; Baha H; Wang W; Neerukonda SN; Wang T; Weiss CD
    PLoS Pathog; 2023 Nov; 19(11):e1011788. PubMed ID: 37943965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage.
    Minami S; Kotaki T; Sakai Y; Okamura S; Torii S; Ono C; Motooka D; Hamajima R; Nouda R; Nurdin JA; Yamasaki M; Kanai Y; Ebina H; Maeda Y; Okamoto T; Tachibana T; Matsuura Y; Kobayashi T
    Microbiol Spectr; 2024 Apr; 12(4):e0285923. PubMed ID: 38415690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype.
    Barut GT; Halwe NJ; Taddeo A; Kelly JN; Schön J; Ebert N; Ulrich L; Devisme C; Steiner S; Trüeb BS; Hoffmann B; Veiga IB; Leborgne NGF; Moreira EA; Breithaupt A; Wylezich C; Höper D; Wernike K; Godel A; Thomann L; Flück V; Stalder H; Brügger M; Esteves BIO; Zumkehr B; Beilleau G; Kratzel A; Schmied K; Ochsenbein S; Lang RM; Wider M; Machahua C; Dorn P; Marti TM; Funke-Chambour M; Rauch A; Widera M; Ciesek S; Dijkman R; Hoffmann D; Alves MP; Benarafa C; Beer M; Thiel V
    Nat Commun; 2022 Oct; 13(1):5929. PubMed ID: 36207334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spike mutation D614G alters SARS-CoV-2 fitness.
    Plante JA; Liu Y; Liu J; Xia H; Johnson BA; Lokugamage KG; Zhang X; Muruato AE; Zou J; Fontes-Garfias CR; Mirchandani D; Scharton D; Bilello JP; Ku Z; An Z; Kalveram B; Freiberg AN; Menachery VD; Xie X; Plante KS; Weaver SC; Shi PY
    Nature; 2021 Apr; 592(7852):116-121. PubMed ID: 33106671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection.
    Letarov AV; Babenko VV; Kulikov EE
    Biochemistry (Mosc); 2021 Mar; 86(3):257-261. PubMed ID: 33838638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
    Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
    J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.
    Katte RH; Ao Y; Xu W; Han Y; Zhong G; Ghimire D; Florence J; Tucker TA; Lu M
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and evaluation of vaccination strategies for addressing the continuous evolution SARS-CoV-2 based on recombinant trimeric protein technology: Potential for cross-neutralizing activity and broad coronavirus response.
    Du P; Li N; Tang S; Zhou Z; Liu Z; Wang T; Li J; Zeng S; Chen J
    Heliyon; 2024 Jul; 10(14):e34492. PubMed ID: 39148990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of SARS-CoV-2 Spike Protein Variants with Recombinant Reporter Viruses Created from a Bacmid System.
    Cordsmeier A; Jungnickl D; Herrmann A; Korn K; Ensser A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
    Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
    Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative SARS-CoV-2 Omicron BA.5 variant and D614G-Wuhan strain infections in ferrets: insights into attenuation and disease progression during subclinical to mild COVID-19.
    Barroso-Arévalo S; Sánchez-Morales L; Porras N; Díaz-Frutos M; Barasona JA; Isla J; López D; Gortázar C; Domínguez L; Sánchez-Vizcaíno JM
    Front Vet Sci; 2024; 11():1435464. PubMed ID: 39211479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.
    Sasaki M; Toba S; Itakura Y; Chambaro HM; Kishimoto M; Tabata K; Intaruck K; Uemura K; Sanaki T; Sato A; Hall WW; Orba Y; Sawa H
    mBio; 2021 Aug; 12(4):e0141521. PubMed ID: 34425707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells.
    Bugatti A; Filippini F; Messali S; Giovanetti M; Ravelli C; Zani A; Ciccozzi M; Caruso A; Caccuri F
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.